In a nutshell This study examined how safe and effective brentuximab vedotin (Adcedris) is when added to conventional treatments for relapsed and unresponsive Hodgkin lymphoma. This study concluded that this treatment is safe and effective when used as part of the treatment for Hodgkin lymphoma. Some background Standard treatment for...
Read MoreCurrent treatment status-Undergoing active treatment-No response Posts on Medivizor
Sintilimab in relapsed or unresponsive Hodgkin lymphoma
In a nutshell This study examined the safety and effectiveness of sintilimab in patients with relapsed or unresponsive Hodgkin lymphoma. This study concluded that sintilimab could be a new treatment option for these patients. Some background Hodgkin disease (HD) is a type of lymphoma. In patients who relapse or do not respond to first-line...
Read MoreEvaluating the long-term outcomes of Zevalin for patients with advanced B cell lymphoma
In a nutshell This study evaluated the long-term outcomes of patients with advanced (stage 3 – 4) non-Hodgkin’s lymphoma (NHL) who received radioimmunotherapy before allogeneic stem cell transplantation (alloSCT). This study concluded that this treatment regimen improved survival in most of these patients. Some background AlloSCT involves...
Read MoreVenetoclax-rituximab combination improves survival in patients with unresponsive and relapsed chronic lymphocytic leukemia
In a nutshell This study looked at the effectiveness of venetoclax-rituximab (Venclexta–Rituxan) in patients with unresponsive or relapsed chronic lymphocytic leukemia (CLL). Researchers found that this treatment improved survival in patients with CLL. Some background Chronic lymphocytic leukemia is a cancer of the bone marrow. This can...
Read MoreEvaluating the safety and effectiveness of axicabtagene ciloleucel for unresponsive B-cell lymphoma
In a nutshell This study looked at the safety and effectiveness of axicabtagene ciloleucel (AC; Yescarta) in the treatment of unresponsive B-cell lymphoma. Researchers found that AC is a safe and effective treatment for these patients. Some background B-cell lymphoma is a cancer of cells in the immune system. It is treated with medication that targets...
Read MoreEvaluating a new targeted therapy with or without itacitinib for relapsed or refractory lymphoma
In a nutshell This study evaluated the safety and effectiveness of a new targeted therapy (INCB040093) with or without itacitinib in patients with relapsed or refractory (does not respond to treatment) lymphoma. This study concluded that this new agent was well-tolerated and showed promising effectiveness in these patients. Some background...
Read MoreEvaluating brentuximab vedotin plus gemcitabine in children and young adults with relapsed or refractory Hodgkin’s lymphoma
In a nutshell This study evaluated the safety and effectiveness of brentuximab vedotin (Adcetris) plus gemcitabine (Gemzar) in children and young adults with relapsed or refractory (does not respond to treatment) Hodgkin’s lymphoma (HL). This study concluded that this combination is safe and shows promising effectiveness in these...
Read MoreAdding inotuzumab ozogamicin with or without blinatumomab to chemotherapy for ALL.
In a nutshell This study looked at the effectiveness of adding inotuzumab ozogamicin (Besponsa) and blinatumomab (Blincyto) to low-intensity chemotherapy in the treatment of ALL. Researchers found that this combination of treatment was effective in these patients. Some background Acute lymphoblastic leukemia (ALL) is a cancer of the bone marrow. This...
Read MoreIs blinatumomab safe and effective in the treatment of ALL?
In a nutshell This study looked at the safety and effectiveness of blinatumomab (Blincyto) in the treatment of unresponsive acute lymphoblastic leukemia (ALL). Researchers found that blinatumomab was safe and effective in the treatment of these patients. Some background Acute lymphoblastic leukemia is a type of cancer of the bone marrow. This can lead...
Read MoreIs regorafenib a safe option for the treatment of metastatic colorectal cancer?
In a nutshell This study investigated the effectiveness and safety of regorafenib (Stivarga) to treat patients with metastatic (spread to other parts of the body) colorectal cancer (mCRC) that progressed after initial treatment. Researchers suggested that regorafenib is a safe option to treat these patients. Some background The standard treatment...
Read MoreTreatment options for patients with relapsed or refractory DLBCL
In a nutshell This article reviewed current treatment options for patients with relapsed (cancer recurrence) or refractory (does not respond to treatment) diffuse large B-cell lymphoma (DLBCL). Some background DLBCL is one of the most common types of non-Hodgkin’s lymphoma. Typical first-line (primary) treatment involves chemoimmunotherapy....
Read MoreEvaluating the long-term outcomes of brentuximab vedotin after stem cell transplantation for classical Hodgkin’s lymphoma
In a nutshell This study evaluated the long-term survival and safety of brentuximab vedotin (Adcetris) treatment for patients with classical Hodgkin’s lymphoma (cHL) after autologous stem cell transplantation (auto-SCT; patient's own healthy stem cells are retrieved and then returned into the body after cancer has been removed with chemotherapy...
Read More
